Adam Cohen, MD

Adam D. Cohen, MD, discusses ongoing research influencing the multiple myeloma treatment landscape.

Adam D. Cohen, MD, discusses the different chimeric antigen receptor T-cell therapies used for multiple myeloma treatment and delves into their potential benefits and risks.

Adam D. Cohen, MD, discusses the new era of multiple myeloma treatment with bispecifics and CAR T-cell therapy.

Adam Cohen, MD, discusses the adverse events of concern associated with B-cell maturation antigen–targeted therapies for relapsed/refractory multiple myeloma.

Adam Cohen, MD, discusses when patients should receive chimeric antigen receptor T-cell therapies for relapsed/refractory multiple myeloma.

Adam Cohen, MD, discusses the current FDA-approved BCMA-directed therapies in the multiple myeloma space and the clinical data supporting each agent.